Filtered By:
Therapy: Chemotherapy
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 451 results found since Jan 2013.
E-152 Neurointervention in the pediatric population: 18-years experience from a single center
ConclusionsAt out institution, multidisciplinary interaction allowed the treatment of a wide variety of cerebrovascular diseases in the pediatric population. Pediatric patients carry high complication risks due to frequent presence of systemic conditions, but joined experience from pediatric neurology, neurosurgery and neurointervention departments allow their treatment with optimal planning and results.Abstract E-152 Table 1Intracranial aneurysms Variable Value Age at diagnosis, mean (SD) or median (IQR) 16 (16–19) Male:Female 12:10 Associated conditions•Moya moya•Connective tissue disorder•Von Wille...
Source: Journal of NeuroInterventional Surgery - July 23, 2022 Category: Neurosurgery Authors: Donnelly, B., Monteiro, A., Recker, M., Khawar, W., Waqas, M., Cappuzzo, J., Reynolds, R., Siddiqui, A., Levy, E. Tags: SNIS 19th annual meeting electronic poster abstracts Source Type: research
Cardiovascular Disease in Adult Cancer Survivors: a Review of Current Evidence, Strategies for Prevention and Management, and Future Directions for Cardio-oncology
AbstractPurpose of ReviewCardiovascular disease is long-term complication of both cancer and anti-cancer treatment and can have significant ramifications for health-related quality of life and mortality. This narrative review explores the current evidence linking cardiovascular disease and cancer, as well as exploring strategies for the prevention and management of cardiovascular disease, and outlines future opportunities in the field of cardio-oncology.Recent FindingsCancer confers risk for various cardiovascular diseases including heart failure, cardiomyopathy, arrhythmia, coronary heart disease, stroke, venous thromboem...
Source: Current Oncology Reports - July 7, 2022 Category: Cancer & Oncology Source Type: research
Recent Synergy of Nanodiamonds: Role in Brain-Targeted Drug Delivery for the Management of Neurological Disorders
AbstractThe aim of the present review article is to summarize the role of nanodiamonds in various neurological diseases. We have taken related literature of making this review article from ScienceDirect, springer, Research gate, PubMed, Sci-finder, etc. The current approaches for treating neurological conditions such as glioblastoma includes chemotherapy or combination anti-retro viral therapy for HIV (human immunodeficiency virus) or use of anti-Alzheimer drugs during cognitive impairment. These approaches can provide only symptomatic relief as they do not target the cause of the disease due to their inability to penetrat...
Source: Molecular Neurobiology - May 27, 2022 Category: Neurology Source Type: research
Why Acupuncture Is Going Mainstream in Medicine
When the opioid addiction crisis began to surge in the U.S. about a decade ago, Dr. Medhat Mikhael spent a lot of time talking to his patients about other ways to heal pain besides opioids, from other types of medications to alternative treatments.
As a pain management specialist at MemorialCare Orange Coast Medical Center in Fountain Valley, Calif., he didn’t anticipate leaving behind the short-term use of opioids altogether, since they work so well for post-surgical pain. But he wanted to recommend a remedy that was safer and still effective.
That turned out to be acupuncture.
“Like any treatment, acupuncture...
Source: TIME: Health - April 29, 2022 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized healthscienceclimate medicine Source Type: news
Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study
CONCLUSION: Women with BC had increased incidence of CVD events, CVD-related mortality, and all-cause mortality compared with women without BC, and risks varied according to the history of cancer treatment received. Studies are needed to determine how women who received BC treatment should be cared for to improve cardiovascular outcomes.PMID:35385342 | DOI:10.1200/JCO.21.01736
Source: Clinical Genitourinary Cancer - April 6, 2022 Category: Cancer & Oncology Authors: Heather Greenlee Carlos Iribarren Jamal S Rana Richard Cheng Mai Nguyen-Huynh Eileen Rillamas-Sun Zaixing Shi Cecile A Laurent Valerie S Lee Janise M Roh Margarita Santiago-Torres Hanjie Shen Dawn L Hershman Lawrence H Kushi Romain Neugebauer Marilyn L Kw Source Type: research
Drugs Used for Nausea/Vomiting Linked to Stroke Risk Drugs Used for Nausea/Vomiting Linked to Stroke Risk
Antidopaminergic antiemetics (ADAs) used to relieve nausea and vomiting, including that induced by chemotherapy or radiotherapy, have been associated with an increased risk of ischemic stroke.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - March 29, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
A review on the neuroprotective effect of berberine against chemotherapy-induced cognitive impairment
Curr Drug Targets. 2022 Mar 3. doi: 10.2174/1389450123666220303094752. Online ahead of print.ABSTRACTChemobrain is one of the major side effects of chemotherapy, despite increased research, the mechanisms underlying chemotherapy-induced cognitive changes remain unknown. Though, several possibly important candidate mechanisms have been identified and will be studied further in the future. Chemobrain is characterized by memory loss, cognitive impairment, difficulty in language, concentration, acceleration, and learning. The major characteristic of chemobrain is oxidative stress, mitochondrial dysfunction, immune dysregulatio...
Source: Current Drug Targets - March 4, 2022 Category: Drugs & Pharmacology Authors: Kuleshwar Sahu Sukhdev Singh Bhawna Devi Charan Singh Arti Singh Source Type: research
Janssen Data at ASCO GU Demonstrate Longstanding Leadership in Prostate Cancer and Commitment to Advancing Potential New Therapeutic Options for Genitourinary Cancers
Raritan, NJ, Feb. 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that 17 presentations will be featured at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place in San Francisco and virtually from February 17-19. Building on its long-term leadership in prostate cancer, Janssen is committed to advancing innovative treatments and transforming patient experiences, while focusing on research that may drive better outcomes for people across the genitourinary cancer spectrum. Data to be presented include Phase 3 results for the selective ...
Source: Johnson and Johnson - February 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
